Skip to content

UFP Technologies

US · UFPT #2677 by market cap Listed 1970
290.85 -8.08 -2.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Near fair value
212.04 fair value ≈ 276.20 340.37
  • Implied fair-value range of 212.04-340.37, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +5.3% above the average-multiple fair value of 276.20.

Valuation each multiple against its own 5-year range

P/B ratio 4.87 In line with history 62nd percentile
5-year average 4.69 · #87 of 126 in Medical Devices
P/E ratio 31.16 In line with history 54th percentile
5-year average 31.57 · forward 27.89 · #25 of 39 in Medical Devices
P/S ratio 3.64 Expensive vs history 74th percentile
5-year average 3.38 · forward 3.41 · #87 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
UFP Technologies (UFPT) 2.25B 29.71 4.64 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value277.72 Economic moatNarrow UncertaintyHigh

Trading 4.5% above Morningstar's fair value estimate.

Fair value

UFP Technologies Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 10% premium over our quantitative fair value estimate of $277.72 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 20.7%, which ranks in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 3.5%, for example, lies in the bottom 45% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:18 · For reference only, not investment advice and not tailored to your situation.

UFP Technologies discussion 0 comments

Add a comment